These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 15988404

  • 1. [Methimazole versus methimazole and diphosphonates in hyperthyroid and osteoporotic patients].
    Lupoli GA, Fittipaldi MR, Fonderico F, Panico A, Colarusso S, Di Micco L, Cavallo A, Costa L, Paglione A, Lupoli G.
    Minerva Endocrinol; 2005 Jun; 30(2):89-94. PubMed ID: 15988404
    [Abstract] [Full Text] [Related]

  • 2. Osteoporosis treatment in elderly hyperthyroid male patients.
    Fittipaldi MR, Fonderico F, Vitale G, Ciccarelli A, Lupoli GA, Cascella T, Panico A, Lupoli G.
    J Endocrinol Invest; 2002 Jun; 25(10 Suppl):98-100. PubMed ID: 12508936
    [No Abstract] [Full Text] [Related]

  • 3. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 4. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
    Yang LJ, Shen FX, Zheng JC, Zhang HL.
    Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
    [Abstract] [Full Text] [Related]

  • 5. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C.
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
    Pantazi H, Papapetrou PD.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
    [Abstract] [Full Text] [Related]

  • 11. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 12. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 13. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA.
    J Oncol Pharm Pract; 2005 Jun 30; 11(2):51-6. PubMed ID: 16460605
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism.
    Lakatos P, Foldes J, Nagy Z, Takacs I, Speer G, Horvath C, Mohan S, Baylink DJ, Stern PH.
    Thyroid; 2000 May 30; 10(5):417-23. PubMed ID: 10884189
    [Abstract] [Full Text] [Related]

  • 17. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 30; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 18. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 19. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z, Karadag-Saygi E, Unlu-Ozkan F, Akyuz G.
    Aging Male; 2007 Dec 01; 10(4):197-201. PubMed ID: 18033629
    [Abstract] [Full Text] [Related]

  • 20. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug 01; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.